From Alphastreet - Earnings Decoded. Market Intelligence Delivered · AlphaStreet Newsdesk · · 40s
ALX Oncology Q3 2026 Results
ALX Oncology Holdings reports narrower Q3 2026 loss as clinical trials advance.
In brief
ALX Oncology Holdings reports narrower Q3 2026 loss as clinical trials advance. ALX Oncology Holdings Inc. reported a narrower net loss of $0.15 per share in Q3 2026, down 63.4% from Q3 2025. Originally reported by Alphastreet - Earnings Decoded. Market Intelligence Delivered.
Q3 2026 Financial Results
ALX Oncology Holdings Inc. reported a narrower loss for the third quarter of 2026.
Net Loss Details
The company posted a net loss of $21.8M for the quarter, translating to a loss of $0.15 per share.
Improvement from Previous Year

The $0.15 per share loss narrowed 63.4% from the $0.41 loss ALX Oncology recorded in the third quarter of 2025.
What to remember
ALX Oncology Holdings Inc. reported a narrower net loss of $0.15 per share in Q3 2026, down 63.4% from Q3 2025.
Read the TL;DR — this story on one card.





